Physician profile
Khalida Durrani
NPI 1750386173
$4,692.67
in general payments reported to CMS, 2019-2025
37 companies · $694 in 2025
The $694 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $588 · 2020: $606 · 2021: $574 · 2022: $688 · 2023: $632 · 2024: $910 · 2025: $694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,236.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $975.59 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $778.60 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $520.53 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Pfizer INC. | $307.70 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $288.55 | 2019-2023 | Jardiance |
| Axsome Therapeutics, INC. | $186.51 | 2024 | Auvelity |
| Glaxosmithkline, LLC. | $176.55 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $141.78 | 2019-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $128.21 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $120.44 | 2021-2023 | Xarelto |
| Bausch Health US, LLC | $108.33 | 2022-2024 | Aplenzin, Wellbutrin |
| Bayer Healthcare Pharmaceuticals INC. | $106.85 | 2021-2024 | |
| Amarin Pharma, INC. | $79.87 | 2020-2021 | |
| Vanda Pharmaceuticals INC. | $79.62 | 2022 | |
| Sanofi-Aventis U.S. LLC | $77.39 | 2019-2022 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khalida Durrani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.